胎盘多肽注射液对肺腺癌患者化疗效果的影响

Effect of placenta polypeptide injection on efficacy of chemotherapy for pulmonary adenocarcinoma

目的探讨胎盘多肽注射液对肺腺癌患者化疗效果的影响。方法选取2012年4月至2015年4月间湖北省襄阳市中心医院收治的112例肺腺癌患者,采用随机数表法分为观察组和对照组,每组56例。观察组患者在紫杉醇和顺铂(TP)化疗方案基础上联合胎盘多肽注射液治疗,对照组患者采用TP化疗方案治疗,观察两组患者治疗效果、T淋巴细胞亚群水平及不良反应情况。结果治疗前两组患者T细胞亚群水平差异无统计学意义(P>0.05);治疗后观察组患者CD3^+、CD4^+、CD8^+及CD4^+/CD8^+水平均高于对照组,差异有统计学意义(P<0.05)。观察组患者的总有效和不良反应发生率分别为62.5%和16.1%,对照组患者的总有效率和不良反应发生率为48.2%和28.6%,差异均有统计学意义(均P<0.05)。结论胎盘多肽注射液有助于提高肺腺癌患者免疫功能,减轻化疗的不良反应,提高化疗效果,值得临床应用及推广。

Objective To study the clinical effect of placenta polypeptide injection on the efficacy of chemotherapy for pulmonary adenocarcinoma. Methods The 112 patients with pulmonary adenocarcino- ma admitted to Xiangyang Central Hospital, Affiliated Hospital of Hubei College of Arts and Sciences, from April 2012 to April 2015 were selected and randomly divided into an observation group and a control group according to the random number table method, with 56 patients in each group. Patients in the observation group were given placenta polypeptide injection in addition to paclitaxel combined with cisplatin and patients in the control group were only given combined paclitaxel and cisplatin chemotherapy. Efficacy, the level of T lymphocyte subsets and adverse reactions were observed in the two groups. Results There was no signi- cant difference in the the level of T cell subsets between the two groups before the treatment （ P 〉 0. 05 ）. After treatment, the levels of CD3^＋ , CD4^＋ , CD8^＋ and CD4^＋/CD8 ^＋ were higher in the observation group than in the control group （P 〈 0.05 ）. The overall efficacy rate was 62. 5% for the observation group which was significantly higher than 48. 2% of the control group and the incidence of adverse reactions was 16. 1% for the observation group which was significantly lower than 28. 6% of the control group （ all P 〈 0.05 ）. Conclusion Placenta polypeptide injection can improve immune function, reduce the adverse reactions during chemotherapy and promote the efficacy of chemotherapy in patients with lung adenocarcinoma, which is worthy of clinical application and promotion.